Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12470338 | 0.84 | PIK3CD (0.42) | PIK3CDBCL2MAP4K4PDE4APDE4C | |
| SCHEMBL2010635 | 0.83 | PIK3CD (0.44) | PIK3CDBCL2MAP4K4PDE4APDE4C | |
| SCHEMBL2013331 | 0.83 | PIK3CD (0.44) | PIK3CDBCL2MAP4K4 | |
| SCHEMBL12469976 | 0.80 | PIK3CD (0.43) | PIK3CDBCL2MAP4K4PDE4APDE4C | |
| SCHEMBL15621512 | 0.80 | PIK3CD (0.43) | PIK3CDBCL2MAP4K4 | |
| SCHEMBL2018305 | 0.78 | SCN9A (0.36) | PIK3CDNR1H2NR1H3MAP4K4SCN9A | |
| SCHEMBL15617714 | 0.78 | PIK3CD (0.41) | PIK3CDBCL2MAP4K4PDE4APDE4C | |
| SCHEMBL2016600 | 0.74 | MAP4K4 (0.37) | PIK3CDBCL2NR1H2NR1H3MAP4K4 | |
| SCHEMBL2013344 | 0.74 | MAP4K4 (0.41) | PIK3CDMAP4K4PDE4APDE4CPDE4D | |
| SCHEMBL2016845 | 0.72 | PIK3CD (0.62) | PIK3CDBCL2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | PIK3CD 13/4885BCL2 1174/4885NR1H2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.